NORCROSS, Ga., Feb. 3—SurgiLance, Inc., the United States sales, marketing and distribution subsidiary of SurgiLance Pte Ltd, Singapore, sold in excess of $3 million One-Step Safety Lancets to the healthcare industry during calendar year 2002—a 200-percent increase in sales over its CY 2001 sales of approximately $1 million.
"Our sales growth over the past year clearly suggests that our SurgiLance™ One-Step Safety Lancet is gaining favor among clinicians in the United States," said Hugh Cooper, SurgiLance's chief operating officer.
Cooper said the unique pre-armed capability of SurgiLance's One-Step Safety Lancet makes it a safety lancet that is:
Lancets are commonly used in hospitals, physician offices, laboratories, O&G practices, oncology departments, emergency medical services, nursing homes and blood banks.
The U.S. market for safety lancets is believed to be in the $100 million range. This is expected to more than double within the next few years as healthcare facilities convert from conventional to safety lancets.
On an annual basis, the Centers for Disease Control and Prevention in Atlanta reports that more than 380,000 percutaneous injuries from contaminated sharps occur among healthcare workers annually in the United States, with most happening to members of nursing staffs.
Estimates for all healthcare settings are as high as 600,000—800,000, with approximately half of those accidents going unreported.
Yet, the CDC also says that for every 10 sharps injuries that occur, between 6–8 of them could potentially have been prevented if safer medical devices had been used.
SurgiLance, Inc. was incorporated in November 2000, slightly less than two years after Patrick Yi founded the parent company, SurgiLance Pte Ltd, in January 1999.
Specializing in the design, manufacture and sale of safety medical devices, the company launched its first product, the One-Step Safety Lancet, in September 2000, after approximately 18 months of product research and development in Singapore.
One-Step Safety Lancets are available in five different models, each color-coded for easy identification and different penetration depth to ensure blood flow for various applications and skin types.
In August 2002, the U. S. Patent and Trademark Office awarded SurgiLance Pte Ltd a patent for its One-Step Safety Lancet. In October 2002, the Singapore Registry of Patents granted SurgiLance a patent for the same product. In addition to the U.S. and Singapore, SurgiLance has applied for patents in Europe, Asia and Japan.
Major group purchasing organizations that have One-Step Safety Lancets on their approved list include Premier, Inc., who buys for more than 1,500 hospitals and other healthcare sites throughout the nation, and Broadlane, Inc., who counts among its customers more than 490 acute care hospitals and 1,600 sub-acute facilities.
The Department of Veterans Affairs has also approved the One Step Safety Lancet for use in all VA hospitals in the United States.
Surgilance's One-Step Safety Lancet is available through many major medical/surgical product distributors, including:
This release was published prior to MediPurpose™ changing its name from its prior company name—SurgiLance—in 2006.
© 2012 MediPurpose Private Limited | About Us | Contact Us | Terms of Use
Join MediPurpose on 
